Figure 5.

CRISPR/Cas9-Mediated Gene Editing of Potential Cancer Targets in TNBC Cells

(A) Fluorescent western blot analysis of PLK1 in MDA-MB-231 cells infected with control or all-in-one lentiCRISPR targeting PLK1. Note that cells were harvested 5 days after the initial infection.

(B) lentiCRISPR-mediated gene editing of PLK1 suppresses the growth of cancer cells, largely independent of assay formats. Four days after initial virus infection, cells were harvested and seeded in 24-well plates. Cell proliferation was measured by Celigo Imaging Cytometer (Nexcelom Bioscience) on indicated days post plating (mean ± SD; n = 4). The whole-well images filled in with a green color indicate cell confluence.

(C) Fluorescent western blot analysis of lysates that were harvested from MDA-MB-231 cells infected with all-in-one lentiCRISPR vectors targeting control sequence (sgCon) or those of MELK, KRAS, or MYC. Cells were lysed 4 days after initial infection.

(D) Cells were harvested 3 days after initial all-in-one lentiCRISPR infection and seeded in 24-well plates at the indicated densities. Cell proliferation was measured by cell confluence.